Nifuratel Induces Triple-Negative Breast Cancer Cell G2/M Phase Block and Apoptosis by Regulating GADD45A
Pharmaceuticals · 26.09.2024 · 17 (10) · 1269
DOI: 10.3390/ph17101269 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 26.09.2024. Verfasst von Yuhang Hou und 8 weiteren Autor:innen. Beteiligte Einrichtung: New Drug Screening and Pharmacodynamics Evaluation Center, National Key Laboratory for Multi-Target Natural Drugs, China Pharmaceutical University, N…. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science foundation of Jiangsu Province, Jiangsu Funding Program for Excellent Postdoctoral Talent, National Natural Science Foundation of China.
Abstract (Originalsprache)
(1)
Background
Nifuratel (NF113), derived from nitrofuran, has a specific anti-tumor effect. However, the potential mechanisms of NF113 in triple-negative breast cancer remain unknown. (2)
Methods
In the study, CCK8 assay and colony formation assays were used to evaluate the inhibition effect of NF113 on cell proliferation. Apoptosis and cell cycle distribution were tested by flow cytometry. The mechanism of NF113’s anti-tumor effect was predicted by transcriptome sequencing and verified by using PCR and Western blot experiments. Breast cancer organoids constructed from the patient-derived tumor xenograft model and the MDA-MB-468 xenograft mouse model were established to evaluate the effect of NF113. (3)
Results
Our study showed that NF113 had an anti-tumor effect on triple-negative breast cancer both in vitro and in vivo. NF113 also induced apoptosis and G2/M phase arrest in triple-negative breast cancer cells. Our experimental data further verified that NF113 reduced GADD5A mRNA and protein expression, which were significantly upregulated in breast cancer, with downstream CDC25C and AKT phosphorylation changes. (4)
Conclusions
Our data provided compelling evidence that NF113 inhibited breast cancer growth via upregulating GADD45A.
Conclusion
NF113 was able to exert inhibitory effects on the proliferation of triple-negative breast cancer in vivo and in vitro, which may induce G2/M phase arrest via the GADD45A/CyclinB/CDK1 pathway and apoptosis via GADD45A/JNK/P38.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- New Drug Screening and Pharmacodynamics Evaluation Center, National Key Laboratory for Multi-Target Natural Drugs, China Pharmaceutical University, Nanjing 210000, China.
- Key Laboratory of Straw Comprehensive Utilization and Black Soil Conservation, Ministry of Education, College of Life Sciences, Jilin Agricultural University, Changchun 130118, China.
Förderung
- Natural Science foundation of Jiangsu Province
- Jiangsu Funding Program for Excellent Postdoctoral Talent
- National Natural Science Foundation of China
Zitieren
APA
Hou, Y., Hao, H., Yuan, Y., Zhang, J., Liu, Z., Nie, Y., Zhang, S., Yuan, S., & Yang, M. (2024). Nifuratel Induces Triple-Negative Breast Cancer Cell G2/M Phase Block and Apoptosis by Regulating GADD45A. Pharmaceuticals, 17(10), 1269. https://doi.org/10.3390/ph17101269
Vancouver
Hou Y, Hao H, Yuan Y, Zhang J, Liu Z, Nie Y, et al. Nifuratel Induces Triple-Negative Breast Cancer Cell G2/M Phase Block and Apoptosis by Regulating GADD45A. Pharmaceuticals. 2024;17(10):1269. doi:10.3390/ph17101269
BibTeX
@article{Hou2024,
author = {Hou, Yuhang and Hao, Hongyun and Yuan, Yan and Zhang, Jing and Liu, Zhengrui and Nie, Yimin and Zhang, Shichang and Yuan, Shengtao and Yang, Mei},
title = {Nifuratel Induces Triple-Negative Breast Cancer Cell G2/M Phase Block and Apoptosis by Regulating GADD45A},
journal = {Pharmaceuticals},
year = {2024},
volume = {17},
number = {10},
pages = {1269},
doi = {10.3390/ph17101269}
}
EUVIMED